The therapeutic landscape for second-line chronic lymphocytic leukemia (CLL) has benefited from the introduction of three new therapies since 2014, namely, Imbruvica, Venclexta, and Zydelig. Although these agents have improved the treatment outcomes considerably, most patients eventually stop responding and ultimately die of their disease. The currently available second-line CLL therapies are moderately satisfying in terms of efficacy, safety and tolerability, convenience of administration, and non-clinical factors, yet the remaining unmet need for more-efficacious and better-tolerated therapies presents a significant commercial opportunity

Table of contents

  • Non-Hodgkin's Lymphoma And Chronic Lymphocytic Leukemia - Unmet Need - Detailed, Expanded Analysis (Second-line Chronic-Lymphocytic-Leukemia)
    • Treatment Drivers and Goals
      • Overview
      • Physician Rating of Treatment Drivers and Goals in Second-line Chronic Lymphocytic Leukemia
        • Importance of Efficacy Attributes to Prescribing Decisions in Second-Line Chronic Lymphocytic Leukemia — United States
        • Importance of Efficacy Attributes to Prescribing Decisions in Second-Line Chronic Lymphocytic Leukemia — Europe
        • Importance of Safety and Tolerability Attributes to Prescribing Decisions in Second-Line Chronic Lymphocytic Leukemia — United States
        • Importance of Safety and Tolerability Attributes to Prescribing Decisions in Second-Line Chronic Lymphocytic Leukemia — Europe
        • Importance of Convenience of Administration Attributes to Prescribing Decisions in Second-Line Chronic Lymphocytic Leukemia — United States
        • Importance of Convenience of Administration Attributes to Prescribing Decisions in Second-Line Chronic Lymphocytic Leukemia — Europe
      • Stated Versus Derived Importance of Treatment Drivers and Goals
        • Stated Versus Derived Importance of Key Treatment Drivers and Goals
        • Stated Versus Derived Importance of Key Efficacy, Safety and Tolerability, Convenience of Administration and Non-Clinical Attributes to Prescribing Decisions in Chronic Lymphocytic Leukemia— United States
        • Stated Versus Derived Importance of Key Efficacy, Safety and Tolerability, Convenience of Administration and Non-Clinical Attributes to Prescribing Decisions in Chronic Lymphocytic Leukemia — Europe
    • Product Performance Against Treatment Drivers and Goals
      • Overview
      • Rationale for Drug Selection
        • Therapies for Second-Line Chronic Lymphocytic Leukemia
      • Current Brand Performance on Key Treatment Drivers and Goals
        • Overall Performance of Key Therapies for Second-Line Chronic Lymphocytic Leukemia — United States
        • Overall Performance of Key Therapies for Second-Line Chronic Lymphocytic Leukemia — Europe
        • Relative Performance of Key Therapies for Second-Line Chronic Lymphocytic Leukemia Across Select Efficacy Attributes — United States
        • Relative Performance of Key Therapies for Second-Line Chronic Lymphocytic Leukemia Across Select Efficacy Attributes — Europe
        • Relative Performance of Key Therapies for Second-Line Chronic Lymphocytic Leukemia Across Select Safety and Tolerability Attributes — United States
        • Relative Performance of Key Therapies for Second-Line Chronic Lymphocytic Leukemia Across Select Safety and Tolerability Attributes — Europe
        • Relative Performance of Key Therapies for Second-Line Chronic Lymphocytic Leukemia Across Select Convenience of Administration Attributes — United States
        • Relative Performance of Key Therapies for Second-Line Chronic Lymphocytic Leukemia Across Select Convenience of Administration Attributes — Europe
    • Assessment of Unmet Need
      • Overview
      • Overall Satisfaction with Current Treatment
        • Surveyed Hematological Oncologists' Satisfaction With the Performance of Key Therapies for Second-Line Chronic Lymphocytic Leukemia on Efficacy, Safety and Tolerability, Convenience of Administration, and Non-Clinical Factors — United States
        • Surveyed Hematological Oncologists' Satisfaction With the Performance of Key Therapies for Second-Line Chronic Lymphocytic Leukemia on Efficacy, Safety and Tolerability, Convenience of Administration, and Non-Clinical Factors — Europe
      • Physician Rating of Unmet Need in Second-line Chronic Lymphocytic Leukemia
        • Surveyed Hematological Oncologists' Ascribed Level of Unmet Need Across Key Efficacy Attributes in Second-Line Chronic Lymphocytic Leukemia — United States
        • Surveyed Hematological Oncologists' Ascribed Level of Unmet Need Across Key Efficacy Attributes in Second-Line Chronic Lymphocytic Leukemia — Europe
        • Surveyed Hematological Oncologists' Ascribed Level of Unmet Need Across Key Safety and Tolerability Attributes in Second-Line Chronic Lymphocytic Leukemia — United States
        • Surveyed Hematological Oncologists' Ascribed Level of Unmet Need Across Key Safety and Tolerability Attributes in Second-Line Chronic Lymphocytic Leukemia — Europe
        • Surveyed Hematological Oncologists' Ascribed Level of Unmet Need Across Key Convenience of Administration Attributes in Second-Line Chronic Lymphocytic Leukemia — United States
        • Surveyed Hematological Oncologists' Ascribed Level of Unmet Need Across Key Convenience of Administration Attributes in Second-Line Chronic Lymphocytic Leukemia — Europe
      • Unmet Need in Second-line Chronic Lymphocytic Leukemia and Related Indications
        • Surveyed Hematological Oncologists' Ascribed Level of Unmet Need in Second-Line Chronic Lymphocytic Leukemia and Related Indications — United States
        • Surveyed Hematological Oncologists' Ascribed Level of Unmet Need in Second-Line Chronic Lymphocytic Leukemia and Related Indications — Europe
    • Opportunity Analysis
      • Areas of Opportunity in the Second-line Chronic Lymphocytic Leukemia Market and Emerging Therapy Insights
        • Opportunity: A Novel Therapy That Can Significantly Increase Overall Survival
        • Opportunity: A Therapy That Improves Complete Response Rate
        • Opportunity: A Novel Therapy with an Improved Safety and Tolerability Profile
    • Target Product Profiles
      • Assessing Drug Development Opportunities
      • Target Product Profile Methodology
        • Attributes and Attribute Levels
        • Assigned Prohibitions for the Conjoint Module
      • Attribute Importance and Part-Worth Utilities
        • Second-Line Chronic Lymphocytic Leukemia Target Product Profile: Attribute Importance
        • Second-Line Chronic Lymphocytic Leukemia Target Product Profile: Attribute-Level Part-Worth Utilities
      • Conjoint Analysis-Based Simulations of Market Scenarios
        • Second-Line Chronic Lymphocytic Leukemia Simulations: Share of Preference of Target Product Profiles Included in Scenario 1
        • Second-Line Chronic Lymphocytic Leukemia Market Simulations: Likelihood to Prescribe Target Product Profiles Included in Scenario 1
        • Second-Line Chronic Lymphocytic Leukemia Market Simulations: Target Product Profiles Included in Scenario 1
        • Second-Line Chronic Lymphocytic Leukemia Market Simulations: Share of Preference of Target Product Profiles Included in Scenario 2
        • Second-Line Chronic Lymphocytic Leukemia Market Simulations: Likelihood to Prescribe Target Product Profiles Included in Scenario 2
        • Second-Line Chronic Lymphocytic Leukemia Market Simulations: Target Product Profiles Included in Scenario 2

Author(s): Niamh Buckley

Niamh Buckley Ph.D. is a senior director in the oncology team at Decision Resources Group where she manages a team of analysts in producing syndicated and custom primary and secondary market research on a wide range of oncology indications. She also provides sales and client support for all oncology products.

Dr. Buckley has extensive experience in market access and forecasting across oncology and hematology-oncology drug markets She also has considerable experience in conducting primary research with physicians and payers throughout the major pharmaceutical markets. Prior to joining Decision Resources, Dr. Buckley worked as a postdoctoral scientist focusing on translational breast cancer research. She has a B.Sc. in biotechnology and obtained her Ph.D. in molecular oncology from Trinity College in Ireland.


Related Reports

Non-Hodgkin's Lymphoma And Chronic Lymphocytic Leukemia - Landscape & Forecast - Disease Landscape & Forecast

The launch of several novel therapies and multiple label expansions of premium-priced agents will fuel significant growth of the non-Hodgkin’s lymphoma (NHL) therapy market over the...

View Details

Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia | Disease Landscape and Forecast | G7 | 2020

The launch of several novel therapies and multiple label expansions of premium-priced agents will fuel significant growth of the non-Hodgkin’s lymphoma (NHL) therapy market over the ten-y...

View Details

Non-Hodgkin's Lymphoma And Chronic Lymphocytic Leukemia - Epidemiology - Incyte Proprietary Content

In this project, commissioned by Incyte in February, 2021, we have packaged our published estimates on the epidemiology of NHL & CLL across all the countries in Europe for which we have coverag...

View Details

Non-Hodgkin's Lymphoma And Chronic Lymphocytic Leukemia - Epidemiology - Janssen Proprietary Content

In this project, comissioned by Janssen in December, 2018, we have packaged our published estimates on the epidemiology of CLL - drug treated population across all the countries in Latin Ameri...

View Details